Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

Haematologica

Volumn 97, Issue 1, 2012, Pages 128-132

  Davidoff, Amy J ^a,b   Smith, Sheila Weiss ^a,b   Baer, Maria R ^b   Ke, Xuehua ^a   Bierenbaum, Jason M ^b   Hendrick, Franklin ^a   Mcnally, Diane L ^a   Gore, Steven D ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Characteristics; Erythropoiesis stimulating agent; Myelodys plastic syndromes; Patient; Physician

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG USE; EDUCATION; FEMALE; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAID; MEDICAL SPECIALIST; MYELODYSPLASTIC SYNDROME; NEGRO; PATIENT; PHYSICIAN; RACE DIFFERENCE;

AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC FACTORS; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHYSICIAN'S ROLE; SEER PROGRAM;

EID: 84855218296     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049130     Document Type: Article

References (18)

1. Melchert M, List AF. Management of RBC-transfusion dependence. Hematology Am Soc Hematol Educ Program. 2007:398-404.
2. Mannone L, Gardin C, Quarre MC, Bernard J F, Vassilieff D, Ades L, et al. High-dose dar-bepoetin alfa in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol. 2006;133(5):513-9.
3. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142 (3):379-93.
4. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998(1);92:68-75.
5. Negrin R, Stein R, Doherty K, Cornwell J, Varidman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human gran-ulocyte colony-stimulating factor and ery-thropoietin: evidence for in vivo synergy. Blood. 1996;87(10):4076-81.
6. Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007;137(2):125-32.
7. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IS, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-46.
8. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-51.
9. National Comprehensive Cancer Network Myelodysplastic Syndromes Guidelines. [NCCN website] Available from h t t p:/ /guideline s.nc c n.or g /e p c -guideline/guideline/id/0B60A42F-683E-6522-8648-4FD A3 324FA47? jumpTo=false#;history=4_gls%40F12B780 9-A151-672B-58A4-1CB8F75FF92D_ empty_-1. Accessed April 11, 2011.
10. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, et al. Health, economic, and quality-of-life effects of erythro-poietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321-7.
11. Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68-75.
12. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13): 2191-7.
13. Hosmer D, Lemeshow S. Applied Logistic Regression. 2nd ed. Hoboken, New Jersey: John Wiley and Sons; 2002.
14. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-202.
15. Mahoney T, Kuo YH, Topilow A, Mirhan DJ. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000;135(2):182-5.
16. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP. Effects of health insurance and race on col-orectal cancer treatments and outcomes. Am J Public Health. 2000;90(11):1746-54.
17. Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following the National Comprehensive Cancer Network guidelines. J Natl Compr Canc Netw. 2008; 6(9):942-53.
18. Cubanski J, Huang J, Damico A, Jacobson G, Neuman T. Medicare Chartbook, Pub. n. 8103. 4th ed. Menlo Park, CA: Henry J. Kaiser Family Foundation; 2010.